Nicotinoyl riboside compositions and methods of use
AssigneeCornell University
InventorsAnthony A. Sauve, Tianle Yang Redanz
Life of this patent
Estimating the term…
Abstract
The invention relates to compositions of nicotinoyl ribosides and nicotinamide riboside derivatives and their methods of use. In some embodiments, the invention relates to methods of snaking nicotinoyl ribosides. In some embodiments, the invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinoyl riboside. In further embodiments, the invention relates to methods of using nicotinoyl ribosides and nicotinamide riboside derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival.
Claims22
A method of reducing toxicity induced by a genotoxic agent in a mammal, which method comprises administering to the mammal a therapeutically effective amount of a compound selected from the group consisting of compounds of formula (I):
- and salt complexes thereof, wherein R is selected from the group consisting of —NHMe, —NHEt, —NHCH2CH2OH, —NHCH2CH═CH2, —NHCH(CH3)2, —NHCH2CH2NH2, —NHcyclopropyl, dialkylamino, substituted dialkylamino, alkyloxy, substituted alkyloxy, aryloxy, substituted aryloxy, hydroxylamino, substituted hydroxylamino, O-alkyloxyamino, substituted O-alkyloxyamino, aminooxy, substituted aminoxy, N-alkylaminooxy, substituted N-alkylaminoxy, hydrazino, substituted hydrazino, alkylhydrazino, and substituted alkylhydrazino,
- wherein the mammal has been administered the genotoxic agent in an amount that produces toxicity in the mammal in the absence of the administration of the compound,
- wherein the administration of the compound increases intracellular NAD+ in the mammal and reduces the toxicity in the mammal.
A method of reducing toxicity induced by a genotoxic agent in a mammal, which method comprises administering to the mammal a therapeutically effective amount of a compound selected from the group consisting of compounds of formula (I):
- and salt complexes thereof, wherein R is selected from the group consisting of —NHMe, —NHEt, —NHCH2CH2OH, —NHCH2CH═CH2, —NHCH(CH3)2, —NHCH2CH2NH2, —NHcyclopropyl, dialkylamino, substituted dialkylamino, alkyloxy, substituted alkyloxy, aryloxy, substituted aryloxy, hydroxylamino, substituted hydroxylamino, O-alkyloxyamino, substituted O-alkyloxyamino, aminooxy, substituted aminoxy, N-alkylaminooxy, substituted N-alkylaminoxy, hydrazino, substituted hydrazino, alkylhydrazino, and substituted alkylhydrazino, and then administering to the mammal the genotoxic agent in an amount that produces toxicity in the mammal in the absence of the administration of the compound, wherein the compound increases intracellular NAD+ in the mammal and whereby toxicity that would have been induced by the genotoxic agent is reduced in the mammal by the administration of the compound.
A method of reducing toxicity induced by an alkylating agent in a mammal exposed to an alkylating agent, which method comprises administering to the mammal a therapeutically effective amount of a compound of formula (I):
- and salt complexes thereof, wherein R is amino,
- wherein the mammal has been administered the alkylating agent in an amount that produces toxicity in the mammal in the absence of the administration of the compound,
- wherein the compound is administered in an amount effective to provide a serum concentration effective to increase intracellular NAD+ in the mammal and thereby reduce the toxicity in the mammal, and
- wherein the compound is administered in an amount from about 0.001 mg/day to about 1000 mg/day.
A method of reducing toxicity induced by an alkylating agent in a mammal, which method comprises administering to the mammal a therapeutically effective amount of a compound of formula (I):
- and salt complexes thereof, wherein R is amino, and then administering to the mammal the alkylating agent in an amount that produces toxicity in the mammal in the absence of the administration of the compound, wherein the compound is administered in an amount effective to provide a serum concentration effective to increase intracellular NAD+ in the mammal and whereby toxicity that would have been induced by the alkylating agent is reduced in the mammal by the administration of the compound,
- wherein the compound is administered in an amount from about 0.001 mg/day to about 1000 mg/day.
Dependencies are inferred from the claim text.